Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $7 | $3 | $5 | $0 |
| - Cash | $5 | $5 | $5 | $10 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | -$2 | $0 | -$9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$1 | -$2 | -$2 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$1 | -$3 | -$2 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.63 | -0.62 | -46.42 | -27.69 |
| % Growth | -1.6% | 98.7% | -67.6% | – |
| Operating Cash Flow | -$1 | -$1 | -$2 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$1 | -$2 | -$1 |